3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Hepatitis C
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
13
Radiosurgery
9
spartalizumab
7
lenvatinib
7
Oxaliplatin
6
Gemcitabine
5
Fluorouracil
5
Radiotherapy
4
Cisplatin
4
Bevacizumab
4
atezolizumab
3
Leucovorin
3
Folfox protocol
3
Doxorubicin
3
gadolinium ethoxybenzyl DTPA
2
fludarabine
2
cabozantinib
2
Nivolumab
2
Mitomycin
2
Electroporation
2
Cyclophosphamide
2
Chemoembolization, Therapeutic
2
tremelimumab
1
toripalimab
1
tocilizumab
1
tislelizumab
1
temsirolimus
1
tazemetostat
1
sitravatinib
1
pirarubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Carcinoma, Hepatocellular
×
elbasvir-grazoprevir drug combination
×
Clear all
NCT04546802
2020-09-14
HATCHeT
Bayside Health
Phase 3
Withdrawn